Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Verastem Inc
(NQ:
VSTM
)
3.320
+0.030 (+0.91%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
231,534
Open
3.330
Bid (Size)
3.200 (10)
Ask (Size)
3.320 (1)
Prev. Close
3.290
Today's Range
3.220 - 3.362
52wk Range
2.600 - 14.22
Shares Outstanding
25,325,551
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 12, 2024
Via
Benzinga
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
July 12, 2024
From
Verastem Oncology
Via
Business Wire
Performance
YTD
-60.00%
-60.00%
1 Month
+2.15%
+2.15%
3 Month
-66.26%
-66.26%
6 Month
-70.28%
-70.28%
1 Year
-63.36%
-63.36%
More News
Read More
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2024
From
Verastem Oncology
Via
Business Wire
VSTM Stock Earnings: Verastem Beats EPS for Q1 2024
May 09, 2024
Via
InvestorPlace
Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes
July 01, 2024
From
Verastem Oncology
Via
Business Wire
VERASTEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Verastem, Inc. on Behalf of Verastem Stockholders and Encourages Investors to Contact the Firm
June 10, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Verastem, Inc. (VSTM)
June 07, 2024
From
Kirby McInerney LLP
Via
Business Wire
7 F-Rated Stocks to Avoid at All Costs in June
June 06, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
May 27, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 27, 2024
Via
Benzinga
Crude Oil Rises 1%; Verastem Shares Slide
May 24, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 24, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
May 24, 2024
Via
Benzinga
Nasdaq Gains 1%; Intuit Shares Plunge
May 24, 2024
Via
Benzinga
Is the Stock Market Open on Memorial Day 2024?
May 24, 2024
Via
InvestorPlace
7 Things to Know About the Upcoming Nvidia (NVDA) Stock Split
May 24, 2024
Via
InvestorPlace
NLST Stock Alert: Micron Faces $445 Million Verdict in Netlist Patent Trial
May 24, 2024
Via
InvestorPlace
Topics
Intellectual Property
Exposures
Intellectual Property
Why Is Verastem (VSTM) Stock Down 62% Today?
May 24, 2024
Via
InvestorPlace
Dow Surges 50 Points; US Durable Goods Orders Increase In April
May 24, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
May 24, 2024
Via
Benzinga
Exposures
Product Safety
Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
May 24, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 24, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 24, 2024
Via
InvestorPlace
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
May 24, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer
May 23, 2024
From
Verastem Oncology
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.